--- res: bibo_abstract: - "Background: Atopics have a lower risk for malignancies, and IgE targeted to tumors is superior to IgG in fighting cancer. Whether IgE-mediated innate or adaptive immune surveillance can confer protection against tumors remains unclear.\r\nObjective: We aimed to investigate the effects of active and passive immunotherapy to the tumor-associated antigen HER-2 in three murine models differing in Epsilon-B-cell-receptor expression affecting the levels of expressed IgE.\r\nMethods: We compared the levels of several serum specific anti-HER-2 antibodies (IgE, IgG1, IgG2a, IgG2b, IgA) and the survival rates in low-IgE ΔM1M2 mice lacking the transmembrane/cytoplasmic domain of Epsilon-B-cell-receptors expressing reduced IgE levels, high-IgE KN1 mice expressing chimeric Epsilon-Gamma1-B-cell receptors with 4-6-fold elevated serum IgE levels, and wild type (WT) BALB/c. Prior engrafting mice with D2F2/E2 mammary tumors overexpressing HER-2, mice were vaccinated with HER-2 or vehicle control PBS using the Th2-adjuvant Al(OH)3 (active immunotherapy), or treated with the murine anti-HER-2 IgG1 antibody 4D5 (passive immunotherapy).\r\nResults: Overall, among the three strains of mice, HER-2 vaccination induced significantly higher levels of HER-2 specific IgE and IgG1 in high-IgE KN1, while low-IgE ΔM1M2 mice had higher IgG2a levels. HER-2 vaccination and passive immunotherapy prolonged the survival in tumor-grafted WT and low-IgE ΔM1M2 strains compared with treatment controls; active vaccination provided the highest benefit. Notably, untreated high-IgE KN1 mice displayed the longest survival of all strains, which could not be further extended by active or passive immunotherapy.\r\nConclusion: Active and passive immunotherapies prolong survival in wild type and low-IgE ΔM1M2 mice engrafted with mammary tumors. High-IgE KN1 mice have an innate survival benefit following tumor challenge.@eng" bibo_authorlist: - foaf_Person: foaf_givenName: Josef foaf_name: Singer, Josef foaf_surname: Singer orcid: 0000-0002-8701-2412 - foaf_Person: foaf_givenName: Gertrude foaf_name: Achatz-Straussberger, Gertrude foaf_surname: Achatz-Straussberger - foaf_Person: foaf_givenName: Anna foaf_name: Bentley-Lukschal, Anna foaf_surname: Bentley-Lukschal - foaf_Person: foaf_givenName: Judit foaf_name: Fazekas-Singer, Judit foaf_surname: Fazekas-Singer foaf_workInfoHomepage: http://www.librecat.org/personId=36432834-F248-11E8-B48F-1D18A9856A87 orcid: 0000-0002-8777-3502 - foaf_Person: foaf_givenName: Gernot foaf_name: Achatz, Gernot foaf_surname: Achatz - foaf_Person: foaf_givenName: Sophia N. foaf_name: Karagiannis, Sophia N. foaf_surname: Karagiannis - foaf_Person: foaf_givenName: Erika foaf_name: Jensen-Jarolim, Erika foaf_surname: Jensen-Jarolim bibo_doi: 10.1016/j.waojou.2019.100044 bibo_issue: '7' bibo_volume: 12 dct_date: 2019^xs_gYear dct_isPartOf: - http://id.crossref.org/issn/1939-4551 dct_language: eng dct_publisher: Elsevier@ dct_title: 'AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice@' ...